The Novella Clinical team brings an average of 25 years of industry experience to our customers.
Richard Staub is president of Novella Clinical and serves as a member of the Quintiles’ Clinical Development Leadership Team. Instrumental in establishing Novella Clinical as a premier provider of CRO and staffing services to the clinical research industry, Mr. Staub served as both president and CEO prior to Novella’s 2013 acquisition by Quintiles.
Before joining Novella in 2004, Mr. Staub was senior vice president of global business development at one of the world’s largest clinical research organizations. Mr. Staub’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he had progressive responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.
In 2011 he was named the Ernst & Young Entrepreneur of the Year Carolinas winner, which celebrates entrepreneurs who transform economies, drive innovation and change communities.
Active in multiple civic and nonprofit groups, Mr. Staub currently serves as a board member for the Tammy Lynn Center for Developmental Disabilities.
Rob King is Novella Clinical’s chief operating officer, where he is responsible for global oversight of the company’s project management, clinical, regulatory and data services.
Prior to joining Novella Clinical in 2006, Mr. King held multiple executive-level positions within the clinical research industry. During that time he managed US and European operations as well as regulatory and quality assurance departments.
Mr. King sits on the Data & Technology Coordinating Center (DTCC) Clinical Research Advisory Board and has been an active member since 2003. He has also served as faculty and an advisory board member at several local universities. Mr. King holds a B.A. from the University of North Carolina at Wilmington.
Charles Lambert is chief financial officer for Novella Clinical and oversees all aspects of the company’s financial operations. As an integral part of the executive management team, he develops strategies to maintain Novella’s fiscal health and strong growth trajectory.
Prior to joining Novella Clinical, Mr. Lambert spent 12 years in the healthcare IT sector, serving as CFO for Misys Healthcare Systems and Capario. Throughout his career, he has held numerous executive-level positions within the healthcare, technology and industrial sectors across the US, Europe and Asia. Mr. Lambert graduated from Cambridge University in the United Kingdom and is a qualified Chartered Accountant.
Nick Dyer serves as chief commercial officer where he is responsible for growth and diversification strategies for Novella Clinical. He manages the global business development team as well as the proposals and contracts group.
Prior to joining Novella, Mr. Dyer was vice president, drug development partnerships at Quintiles where he was responsible for the sales, operations and financial performance of partnership activities.
A graduate of the British National Health Service (NHS) general management post graduate program, Mr. Dyer holds a Bachelor’s Degree in Economics from the University of Greenwich, London, and is a Chartered Public Finance Accountant.
Dr. Frank Santoro is Novella Clinical’s chief medical officer and has more than 25 years’ clinical research experience. As a physician and clinical researcher, he offers valuable insights into protocol strategy and study design for Novella’s customers. Prior to joining Novella Clinical in 2008, Dr. Santoro served as vice president, clinical development and medical affairs for Protherics, a UK-based biopharmaceutical company specializing in oncology and critical care products.
Dr. Santoro has served as a project physician for more than 100 domestic and international studies, and directed project team activities for numerous multi-therapeutic Phase I-IV research programs. He has extensive experience managing global operations having directed global project management, clinical monitoring, pharmacovigilance, regulatory and biometric services.
Fiona Markwood is executive vice president of oncology project management for Novella Clinical. She is responsible for developing and guiding strategic direction for the Oncology Division; she oversees all clinical projects and provides executive oversight, ensuring aggressive project timelines are met and all deliverables exceed customer expectations. Ms. Markwood has more than 24 years in the pharmaceutical industry with over 19 years of operations management experience within clinical research at both large pharma and CROs, most recently serving successively as vice president of global strategic alliances and vice president of global project management for a large, global CRO. Ms. Markwood completed her postbaccalaureate MSP at Bryn Mawr College and earned her undergraduate degree from William Smith College in New York.
Tina Siemens is responsible for the global clinical monitoring division at Novella Clinical. With more than 20 years of industry experience, Ms. Siemens brings an extensive background in clinical trial management, project management and clinical monitoring. Most recently she served as Vice President, North American Clinical Operations, for a global clinical research organization. Ms. Siemens earned a B.S. in Nursing from the University of North Carolina at Chapel Hill.
Rob Stallings leads Novella Clinical Resourcing (NCR), which delivers customized staffing and functional outsourcing services to the pharmaceutical, medical device and biotechnology industries in North America and Europe. With more than 20 years of healthcare and pharmaceutical resourcing and outsourcing experience, Mr. Stallings provides both strategic guidance and day-to-day operational leadership for NCR’s global staff.
Prior to joining NCR, Mr. Stallings served as executive vice president at a major US-based clinical staffing firm with responsibility for the company’s overall operations. He also worked for a leading health care recruiting firm as a physician recruiter and held various leadership roles in operations, business development and communications.
Anusha Bala, BSc, LLB, is responsible for leading Novella Clinical’s global regulatory affairs department. She oversees regulatory clinical research projects, safety reporting for oncology and medical device customers, and provides the project team with guidance, training and strategic planning. Ms. Bala has more than 15 years of regulatory affairs experience globally across many therapeutic areas including oncology, CNS and respiratory research. Prior to joining Novella, Ms. Bala held senior regulatory affairs roles at a variety of organizations including the Medicines and Healthcare products Regulatory Agency (MHRA) and two global CROs. Ms. Bala has a BSc in medicinal chemistry and was academically qualified as a barrister in 2007.
David Novotny is senior vice president of Novella Clinical’s Medical Device & Diagnostics Division and has more than 17 years of clinical research experience in hospital, CRO and medical device and biopharma environments. He is responsible for the oversight, strategy and operational success of all medical device and diagnostics sponsor programs globally, including clinical execution and governance management. Prior to joining Novella in 2007, Mr. Novotny served as the US head of operations for a global vascular device company in Chelsea, England.
Mr. Novotny’s therapeutic areas of experience include cardiovascular, vascular, gastroenterology, endocrinology, urology, CNS, orthopedic, neurology, wound care and dermatology. He is a graduate of the University of Iowa with a Bachelor of Science in Exercise Science and an emphasis on physiology and business management.
European and Asian Operations
Based in Novella’s European headquarters in Stevenage, England, Dr. Chris Smyth oversees clinical research and operations in Europe and Asia. Dr. Smyth has more than 20 years’ research and development experience in the pharmaceutical industry. He has led clinical research organizations and biopharmaceutical companies in both Europe and the US, dealing exclusively in hematology and oncology drug development since 2003.
Dr. Smyth earned his Ph.D. in Reproductive Biology from the University of Edinburgh and an M.B.A. from Henley Management College, United Kingdom.